I got really discouraged after reading this article :| weren't last results from Toca511 and DCVax kinda optimistic? And anyone knows if there are any preliminary results from the trial that combined vaccines with checkpoint inhibitors?
What did you find discouraging about the article? The final comments by Platten? This article was about the phase 3 DCVax trial, see here for previous discussion: https://btcocktails.blogspot.com/2018/05/dcvax-update.html
The trial hasn't been unblinded yet, so all comments are about the entire trial population (those who got vaccine upfront as well as those who got placebo upfront with the option of vaccine at recurrence). The primary endpoint of the trial was progression-free survival, which hasn't been reported yet at all, because of the trial not being unblinded yet. It's too early to give a full evaluation of the trial. The thing to look for in these trial is not necessarily the median survival, but the tail of long term survivors in the 5-7 year range. Preliminary result are positive in this regard (as they were in the Toca trials, which weren't randomized).
I haven't seen any results, not even preliminary results or abstracts, on the combination of vaccines or viral therapies with checkpoint inhibitors for glioma. The furthest along is DNX-2401 + pembrolizumab, which opened mid 2016. https://clinicaltrials.gov/ct2/show/NCT02798406
Pembrolizumab with or without HSPPC-96 vaccine opened early 2017 https://clinicaltrials.gov/ct2/show/NCT03018288
I've seen no results yet for either of these trials
This is a pretty nice DCVax write-up (though from a conflicted source due to author's association with a hedge fund which is invested in the biotech company owning DCVax, so also to be read as such):
I got really discouraged after reading this article :| weren't last results from Toca511 and DCVax kinda optimistic? And anyone knows if there are any preliminary results from the trial that combined vaccines with checkpoint inhibitors?
ReplyDeleteWhat did you find discouraging about the article? The final comments by Platten?
ReplyDeleteThis article was about the phase 3 DCVax trial, see here for previous discussion:
https://btcocktails.blogspot.com/2018/05/dcvax-update.html
The trial hasn't been unblinded yet, so all comments are about the entire trial population (those who got vaccine upfront as well as those who got placebo upfront with the option of vaccine at recurrence). The primary endpoint of the trial was progression-free survival, which hasn't been reported yet at all, because of the trial not being unblinded yet. It's too early to give a full evaluation of the trial. The thing to look for in these trial is not necessarily the median survival, but the tail of long term survivors in the 5-7 year range. Preliminary result are positive in this regard (as they were in the Toca trials, which weren't randomized).
I haven't seen any results, not even preliminary results or abstracts, on the combination of vaccines or viral therapies with checkpoint inhibitors for glioma. The furthest along is DNX-2401 + pembrolizumab, which opened mid 2016.
Deletehttps://clinicaltrials.gov/ct2/show/NCT02798406
Pembrolizumab with or without HSPPC-96 vaccine opened early 2017
https://clinicaltrials.gov/ct2/show/NCT03018288
I've seen no results yet for either of these trials
I agree with you, even looking at the median survival it's better than contemporary studies. I don't know why people are so negative on the data.
DeleteThis is a pretty nice DCVax write-up (though from a conflicted source due to author's association with a hedge fund which is invested in the biotech company owning DCVax, so also to be read as such):
ReplyDeletehttp://static1.1.sqspcdn.com/static/f/428566/28026405/1542231723430/NWBO+-+White+Paper+Rago_48081593.pdf?token=rR5pmAu4TehqLK0U%2BLSPRCSSEGw%3D
By the way, the DCVax trial seems to be about to get un-blinded very soon now, hopefully with strong results.